Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to provide written informed consent or assent and to comply with study requirements~* Confirmation of PH1 disease~* Meet the 24 hour urine oxalate excretion requirements~* If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 90 days~Exclusion Criteria:~* Clinically significant health concerns (with the exception of PH1) or clinical evidence of extrarenal systemic oxalosis~* Clinically significant abnormal laboratory results~* Known active or evidence of HIV or hepatitis B or C infection~* An estimated GFR of \< 30 mL/min/1.73m\^2 at screening~* Received an investigational agent within 30 days or 5 half-lives before the first dose of study drug or are in follow-up of another clinical study~* History of kidney or liver transplant~* Known history of multiple drug allergies or allergic reaction to an oligonucleotide or GalNAc~* History of intolerance to subcutaneous injection~* Women who are pregnant, planning a pregnancy, or breast-feeding or those of child bearing potential and not willing to use contraception~* History of alcohol abuse within the last 12 months, or unable or unwilling to limit alcohol consumption throughout the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo/Lumasiran (Type: PLACEBO_COMPARATOR): Lumasiran-matching placebo (normal saline \[0.9% NaCl\]) was administered subcutaneously (SC) at Day 1 and Months 1, 2 and 3 during the 6-Month Double-blind (DB) Period, followed by lumasiran SC, 3.0 mg/kg, at Months 6, 7 and 8 during the 3-Month Blinded Treatment Extension Period, followed by lumasiran SC, 3.0 mg/kg, at Month 9 and then every three months during the 51-Month Open-label Extension (OLE) period.
- Lumasiran/Lumasiran (Type: EXPERIMENTAL): Lumasiran was administered SC, 3.0 mg/kg, at Day 1 and Months 1, 2 and 3 during the 6-Month DB Period, followed by lumasiran SC, 3.0 mg/kg at Month 6, and lumasiran-matching placebo SC at Months 7 and 8 during the 3-Month Blinded Treatment Extension Period, followed by lumasiran SC, 3.0 mg/kg, at Month 9 and then every three months during the 51-Month OLE period.

Based on this trial design, predict the completion outcome and termination type (if applicable).